Incidence of Mucormycosis in Post-Covid Patients
DOI:
https://doi.org/10.56056/amj.2025.372Keywords:
Amphotericin B, Diabetes Mellitus, Mucormycosis, Surgical debridementAbstract
Background and objectives: The majority of mucormycosis infections are fatal. It is mainly contracted when people come in touch with fungal spores in the environment. Mucormycosis is mainly associated with immunocompromising diseases or conditions. This study aims to ascertain and compare the outcomes of various treatment approaches for cases of mucormycosis.
Methods: This cross-sectional research was conducted in the Ear, Nose, and Throat (ENT) Department of Rizgary Teaching Hospital located in Erbil, Iraq. Data were collected over a one-year period, from January 2022 to August 2023. Participants in this study were individuals who were previously infected with COVID-19 and now presented with confirmed mucormycosis, diagnosed through biopsy of suspected lesions. Patients received treatment with amphotericin B, administered at a daily dose of 1 milligram per kilogram, given over four to six hours. Surgical debridement was performed in patients who gave approval. Clinical characteristics, treatment modality and outcome of these patients were assessed.
Results: Twenty-six patients were recruited for this study. The mean age of patients was 53.2±14.3. There were more males (57.7%) than females (42.3%). Around 85% of the patients were diabetic. In our study population, the overall mortality rate stood at 23%. The majority of the of them (80%) were among those who received Amphotericin B only. There was a significant association between treatment strategy and mortality (p<0.05).
Conclusions: In this study; rhino-orbital-cerebral cavities were the most typically involved, and diabetes was the primary underlying illness. There was a significant association between treatment modality and mortality rate in this study.
Downloads
References
1. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009;15 Suppl 5:2-9.
2. Kontoyiannis DP, Lewis RE. Agents of mucormycosis and Entomophthoramycosis. Mandell GL, Bennett GE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Churchill Livingstone; 2010. 3257-69.
3. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54 Suppl 1: S8-S15.
4. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosisexternal icon. Clin Infect Dis. 2012;54 Suppl 1: S23-34.
5. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
6. Reid G, Lynch JP 3rd, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med. 2020;41 (1):99-114.
7. Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, Chen J. Mucormycosis in renal transplant recipients: review of 174 reported casesexternal icon. BMC Infect Dis. 2017;17(1): 283.
8. Abdalla A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, De Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudanexternal icon. J Clin Microbiol. 2002; 40(3): 1031–1036.
9. Vallabhaneni S, Mody RK. Gastrointestinal mucormycosis in neonates: a Review. Curr Fungal Infect Rep. 2015; 9: 269-274.
10. Francis JR, Villanueva P, Bryant P, Blyth CC. Mucormycosis in children: review and recommendations for managementexternal icon. J Pediatric Infect Dis Soc. 2018;7(2):159-164.
11. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19 (12): e405-e421.
12. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54 Suppl 1: S55-60.
13. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71 (6):1367-1376.
14. Kontoyiannis DP, Lewis RE. Agents of mucormycosis and Entomophthoramycosis. Mandell GL, Bennett GE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Churchill Livingstone; 2010. 3257-69.
15. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216-24.
16. Gelston CD, Durairaj VD, Simoes EA. Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole. Arch Ophthalmol. 2007;125(6):848-9.
17. Abanamy R, Alsaud A, Alabdulali R, Alsobaie M, Alalwan B, Aljohani S, et al. Clinical characteristics and outcome of mucormycosis: A multi-center retrospective analysis in Saudi Arabia over 11 years. IJID Reg. 2022; 4:152-156.
18. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653. doi:10.1086/432579/
19. Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, Rendón-Ramírez EJ, Ayala-Cortés AS, Fraga-Hernández ML, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis. 2014; 2014:562610. doi:10.1155/2014/562610/
20. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335-342. doi:10.1080/13693780500464930/
21. Bhanuprasad K, Manesh A, Devasagayam E, Varghese L, Cherian LM, Kurien R, et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis. 2021; 111:267-270. doi: 10.1016/j.ijid.2021.08.037/
22. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34. doi: 10.1016/j.cmi.2018.07.011/
23. Stemler J, Hamed K, Salmanton-García J, Rezaei-Matehkolaei A, Gräfe SK, Sal E, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. Mycoses. 2020;63(10):1060-1068. doi:10.1111/myc.13123/
24. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12): e405-e421. doi:10.1016/S1473-3099(19)30312-3/
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Halgurd Aziz Mustafa, Abdulkhaliq Emin , Ammar Muhammed Salih
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
